Friday POW! Pick of the Week: Gilead Sciences (GILD)
Key Highlights
Stock at ~$133; 52-week range of $107.75 to $157.29;
Q1 2026: revenue $6.96B, +4.4% YoY, 1.5% beat; adj. EPS $2.03, +6.3% beat; adj. operating income $3.27B, 46.9% margin, 4.7% beat; operating margin 37.2%, up from 33.5% YoY
Q2 2026 (August 4): Generally Accepted Accounting Principles (GAAP) net loss $10.5B driven by acquisition write-downs; underlying revenue growth strong; HIV and oncology both growing; full-year product sales guidance raised to $30.1B
PrEP sales exceeded $1B in Q2 2026, a new milestone driven by lenacapavir Yes2Go program and growing prevention market awareness
Trodelvy: FDA-approved for first-line metastatic triple-negative breast cancer; FDA approval for first-line metastatic small cell lung cancer in combination with Keytruda; EU approval for first-line metastatic breast cancer
ISLEND-1 and ISLEND-2 Phase 3 trials: once-weekly oral HIV pill (with Merck) suppressed virus, supporting regulatory filings for potentially first long-acting oral HIV prevention
FDA accepted Yeztugo application for once-weekly oral PrEP — potentially first long-acting pill for HIV prevention
Dividend yield ~2.5%; quarterly dividend $0.79/share; Biktarvy patent protection through 2036; lenacapavir patent estate extends beyond that
Gilead Sciences is one of the more quietly compelling setups in large-cap biopharma right now, and the reason it is under the radar for most investors is the same reason we find it attractive. The stock is trading at approximately $130 to $133, down 16% from its 52-week high of $157.29 and sitting in the middle of its 52-week range of $107.75 to $157.29.
Yes, the Q2 2026 results released August 4 showed a $10.5 billion GAAP net loss, which is obviously not what you want to see.
The number sounds catastrophic until you understand it is almost entirely driven by acquisition-related write-downs and upfront payments rather than any deterioration in the company's operations. The underlying business, by contrast, delivered strong revenue growth in HIV and oncology, raised full-year product sales guidance to $30.1 billion, and generated the kind of cash flow that a $163 billion market cap company needs to sustain a 2.5% dividend yield and an active share repurchase program. As you'll see in the following Bloomberg Financial Analysis table, free cash flow (FCF) is estimated to come in around north of $12.5 billion next year (note the arrow). If so, that would be a most alluring 7.6% FCF yield.
[Bloomberg Financial Analysis table — GILD estimates, with the free-cash-flow line arrowed; cash and debt columns at upper far right]
If you look closely on the upper far right, you'll see that it has $8.6 billion in cash versus a bit over $22 billion in debt. Thus, net debt is roughly $13.4 billion. This means that if GILD hits its free cash flow target next year, it could repay nearly all of its debt should it choose to do so.
For the uninitiated, Gilead is the dominant commercial franchise in HIV treatment, with approximately 70% U.S. market share anchored by Biktarvy, the world's most prescribed HIV regimen. GILD also boasts a growing oncology portfolio built around Trodelvy, a CAR-T program through Yescarta and Tecartus. The investment case here is a business with a durable, patent-protected cash flow engine in HIV that is funding both a meaningful dividend and an aggressive oncology transformation. We believe it's currently priced at a discount to its intrinsic value because the accounting complexity of that transformation has blurred the operating quality of the underlying franchise.
The HIV Franchise: The Cash Engine Funding Everything Else
Biktarvy is the gold standard in HIV treatment, generates multiple billions in annual revenue, and carries patent protection through 2036. In pharmaceutical terms, that is a license to print the cash that funds R&D, acquisitions, dividends, and buybacks for the better part of the next decade. The ISLEND-1 and ISLEND-2 Phase 3 trials for its new, once-weekly oral HIV pill (developed jointly with Merck) read out positively at the AIDS 2026 conference in Rio. The data confirmed that the drug suppressed the virus, supporting regulatory filings for what would be the first-of-its-kind HIV therapy.
Trodelvy and the Oncology Transformation
Trodelvy, the antibody-drug conjugate Gilead acquired through its 2020 purchase of Immunomedics for $21 billion, has become the clearest expression of what Gilead's oncology strategy can produce. The drug has now received U.S. FDA approval for first-line metastatic triple-negative breast cancer (i.e. one of the most difficult-to-treat cancers and a historically large unmet need) and has received European Commission approval for the same indication. The U.S. FDA also approved Trodelvy in combination with Keytruda for first-line metastatic non-small cell lung cancer, adding a second large indication that expands the commercial addressable market substantially beyond the original breast cancer label.
These are not incremental label expansions. First-line metastatic triple-negative breast cancer and first-line metastatic small cell lung cancer are among the largest oncology markets by patient volume and revenue potential. Gilead acquired Trodelvy when it had one approved indication, and now it has multiple, with additional Phase 3 trials ongoing in other tumor types. The $21 billion acquisition price, which was criticized at the time as expensive, is looking more defensible with each new approval.
Q2 Net Loss an Accounting Event, Not a Business Event
The headline from Q2 2026 was quite obviously the $10.5 billion GAAP net loss. That number will appear in every screener, valuation tool, and news headline about Gilead for the next several months. To many, it will make the stock look broken to investors who look at GAAP earnings without reading the footnotes. But, that loss is almost entirely a function of acquisition-related charges, such as upfront payments and write-downs associated with a number of acquisitions that are required to be expensed immediately under GAAP accounting rules. While that's the downside, it's also important as investors to keep a long-term mindset and remember that these charges reflect long-duration assets whose value accrues over years.
Management has been explicit about this distinction: excluding acquisition-related upfront payments, the underlying business is on track with the revenue guidance that has been raised to $30.1 billion for the full year. The adjusted operating margin of 46.9% in Q1, one of the highest in large-cap biopharma, is the operating reality of the business. A 46.9% adjusted operating margin on $30 billion in annual revenue produces approximately $14 billion in annual adjusted operating income. The GAAP loss is the accounting artifact of building the oncology business that will sustain the franchise beyond the current decade.
Valuation
Gilead trades at roughly 12-13x adjusted earnings on the underlying operating business, representing a significant discount to large-cap biopharma peers and to the S&P 500 at 20x. The analyst target range of $120 to $165 with an average around $150 implies approximately 14% upside at consensus and 25% at the high. The wide dispersion, Leerink with Market Perform at $127 on one end and Morgan Stanley at $165 on the other, reflects genuine debate about whether the oncology transformation justifies the acquisition spend. We are on the bull side: Trodelvy's first-line approvals in metastatic breast and lung cancer have answered whether the drug reaches the largest markets. Uptake in first-line indications historically bears little resemblance to the niche second-line volumes the bears are modeling.
As you can see in the chart below, GILD achieved a two-year breakout in the spring of 2024. Since then, as is typical when this happens, it's had a robust rally. Naturally, it would have been nice to highlight this one back then but on a forward P/E basis it's just as cheap now as it was when it broke out. From that point, GILD has continued in a steady up-trend, though it has pulled over the last nine months. At this point, it is resting on its 200-day moving average (yellow line). In our appraisal, this is the pause that refreshes and it's poised to run again.
[Price chart — GILD multi-year, the spring-2024 two-year breakout and the 200-day moving average in yellow]
Arguing the Other Side
The most credible bear case is Inflation Reduction Act (IRA) pricing scrutiny on HIV. If Biktarvy is subject to Medicare drug price negotiation before its 2036 patent expiry, the revenue trajectory of the HIV franchise changes materially and the cash generation that funds the oncology transformation shrinks. This is the risk driving Leerink's downgrade and we'd be lying if we said it's completely bogus.
Acquisition integration risk is the second concern: Arcellx, Tubulis, and Oral Medicines in rapid succession each carry their own clinical execution risk, and the $10.5 billion Q2 GAAP loss is the accounting fallout of those commitments. If any acquired pipeline asset fails in development, the write-downs compound.
Despite these risks, we think the bears need to be right about both IRA pricing and acquisition integration simultaneously to justify the current discount. In our view, that is a higher burden of proof than the current price implies.
The Bottom Line
Our take is that GILD represents the dominant HIV franchise in the world at 12-13x adjusted earnings with a 2.5% dividend yield and a first-line oncology portfolio that posted two major approvals in a single quarter. A business generating $14 billion in annual adjusted operating income that the market is pricing at a 16% discount to its 52-week high because a $10.5 billion GAAP accounting charge made the Q2 headline look terrible. It's also a company that raised full-year product sales guidance to $30.1 billion on the same earnings call that produced the GAAP loss.
The setup is a quality franchise at a solid discount, created by accounting complexity rather than business deterioration. The HIV engine funds everything and the oncology transformation is producing approvals faster than the bears anticipated. The pipeline, once-weekly oral HIV treatment, Yeztugo PrEP, GS-2426, additional Trodelvy indications, CAR-T expansion, is the most clinically productive Gilead has assembled in a decade. We anticipate a re-rating to approximately 15-16x adjusted earnings as the GAAP loss normalization removes the mandate-driven selling overhang and the oncology revenue ramp becomes visible in consecutive quarterly results.
We recommend a Buy for Gilead Sciences (GILD)
The Haymaker Team